Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Empa researchers design therapeutic coatings of silver

A high-frequency plasma reactor in which the nanocomposite coatings are deposited on a substrate material.
A high-frequency plasma reactor in which the nanocomposite coatings are deposited on a substrate material.

Abstract:
Strong against bacteria yet body tissue-compatible

Empa researchers design therapeutic coatings of silver

St. Gallen | Posted on July 5th, 2010

Empa researchers have demonstrated how they can adjust process conditions to influence the properties of novel plasma polymer coatings containing silver nanoparticles. Tailor-made films can be generated through a one-step plasma process. The scientists developed these new coatings, which kill bacteria while having no negative effect on human tissue, in the frame of an EU project.

Silver ions are very efficient at killing bacteria, and in contrast to antibiotic drugs they are effective against hundreds of different bacterial strains thanks to different attacking mechanisms. This makes silver ideal as an antibacterial additive for, e.g., implants and wound dressings. The idea that "a little is good, more is better" cannot be adopted to silver in every case, since higher ion concentrations might also damage human cells and tissues. Therefore, surface coatings need to be made with a therapeutically useful range of silver.

One possible solution is offered by the novel nanostructured polymers with integrated silver nanoparticles which a team of Empa scientists led by Enrico Körner and Dirk Hegemann are developing within the frame of an EU Project called EMBEK1 ("polymer-based, multifunctional, bactericidal materials"). In the context of this research work they investigate how varying plasma conditions during deposition influence the film structure and the associated silver ion release that determines the antibacterial effectiveness. The researchers have determined the basics for "designing" tailor-made coatings with desirable properties. The results of this work have recently been published in the scientific journal "Plasma Processes and Polymers".

Silver nanoparticles are firmly incorporated in the plasma layer

The Empa team used a so-called RF Plasma Reactor, in which hydrocarbon coatings can be deposited on different substrates. As raw materials a hydrocarbon gas such as ethylene (C2H4) is mixed with a reactive gas such as carbon dioxide (CO2) in order to obtain a cross-linked plasma polymer matrix containing functional groups required for cell growth. The electrical energy necessary to drive this process is supplied by electrodes. In order to incorporate silver particles firmly in the plasma layer, one of the electrodes is made of pure silver where a high voltage has to be applied for sputtering conditions. Nevertheless, the film deposition occurs near room temperature allowing the treatment of temperature-sensitive materials.

The Empa scientists varied different process parameters such as the ratio of the two gases and the power input. They discovered that raising the ratio of CO2 to C2H4 leads to an increase of the incorporated amount of silver in the coating as well as to smaller, more homogenously distributed particles. Nanometer-sized, well-distributed silver particles have a significantly higher surface area than, for example, a pure silver layer. Increasing the input power also results in a higher incorporation of silver and at the same time increases the size of the incorporated silver particles. Finally, the researchers investigated the quantities of released silver ions of various coatings over different time periods. The obtained data were evaluated in context of the antibacterial and cell test results. A range could thus be determined for the silver nanocomposite coatings within they showed antibacterial properties and were yet found to be cytocompatible (i.e. friendly to cells).

These results can be used to transfer the deposition process from the laboratory scale to Empa's in-house pilot plant, the first step towards industrial production of the tailor-made antibacterial coatings. In addition, the research team is attempting to create coatings with gradients in the silver concentration enabling the controlled release of silver ions over a certain time period. A polymer covering layer would thereby help human cells to grow optimally on the antibacterial coating.


####

About Empa
Empa is an interdisciplinary research and services institution for material sciences and technology development within the ETH Domain. Empa’s research and development activities are oriented to meeting the requirements of industry and the needs of our society, and link together applications-oriented research and the practical implementation of new ideas, science and industry, and science and society.

For more information, please click here

Contacts:
Enrico Körner
Advanced Fibers
Phone +41 71 274 75 63


Dr. Dirk Hegemann
Advanced Fibers
Phone +41 71 274 72 68


Media contact
Beatrice Huber
Empa, Kommunikation
Phone +41 44 823 47 33

Copyright © Empa

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Possible Futures

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project